Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navocaftor - Galapagos NV

Next Previous
X
Search
Drug Profile

Navocaftor - Galapagos NV

Alternative Names: ABBV 3067; GLPG 3067; GLPG0367

Latest Information Update: 23 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer AbbVie; Galapagos NV
  • Class Amines; Antifibrotics; Fluorinated hydrocarbons; Oxadiazoles; Phenyl ethers; Pyridines; Small molecules; Sulfones
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 16 Jul 2024 Sionna Therapeutics in-licenses Navocaftor from AbbVie
  • 22 Jun 2023 Abbvie terminates a phase II trial in Cystic fibrosis (Combination therapy, In adults) due to strategic considerations in United Kingdom, Slovakia, Hungary, Germany, Australia, New Zealand, Czech Republic, Netherlands, Belgium and USA (PO) (NCT04853368)
  • 21 Dec 2022 AbbVie completes a the phase I trial in pharmacokinetics and safety trial in healthy subjects in US (PO) (NCT05538585)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top